BeAI GmbH

BeAI GmbH

Wagniskapital- und Private-Equity-Auftraggeber

Friedrichsdorf, Hesse 78 Follower:innen

BeAI invests in and supports early stage software startups, usually shortly before or shortly after their market entry.

Folgen

Info

BeAI is the holding company of angel investor Nikolaus D. Bayer. We invest in early stage startups, usually shortly before or shortly after their market entry. Beyond financial resources, an essential aspect of each involvment is a steady company as advisor and sparring partner - based on more than 20 years of active entrepreneurial experience. In order to ensure close cooperation, for the time being, new investments must be based in Germany. Our focus is on software ventures, preferably with B2B business models. We are particular fond of topics in the domains of digitalisation, artificial intelligence, process optimisation, operations research, and payments. Ultimately, commercial success counts. On top of this, we love ventures which make this world a better place. Some examples are our past and current investments in green technology (BRT Recycling Technologie, node.energy, sigo), security (Enterpay, IRIS Analytics, Intruder), education (StudySmarter) or better living (Democrance).

Website
https://www.beai.eu
Branche
Wagniskapital- und Private-Equity-Auftraggeber
Größe
1 Beschäftigte:r
Hauptsitz
Friedrichsdorf, Hesse
Art
Privatunternehmen
Gegründet
2017

Orte

Updates

  • BeAI GmbH hat dies direkt geteilt

    Unternehmensseite von Myria Biosciences AG anzeigen, Grafik
    Myria Biosciences AG

    825 Follower:innen

    𝐀𝐈 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐬 𝐍𝐚𝐭𝐮𝐫𝐞'𝐬 𝐓𝐨𝐨𝐥𝐛𝐨𝐱: 𝐌𝐲𝐫𝐢𝐚 𝐁𝐢𝐨𝐬𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐒𝐞𝐜𝐮𝐫𝐞𝐬 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 𝐟𝐨𝐫 𝐒𝐲𝐧𝐭𝐡𝐞𝐭𝐢𝐜 𝐈𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐜𝐞 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝖤𝗑𝖼𝗂𝗍𝗂𝗇𝗀 𝗇𝖾𝗐𝗌 𝖿𝗋𝗈𝗆 𝖬𝗒𝗋𝗂𝖺 𝖡𝗂𝗈𝗌𝖼𝗂𝖾𝗇𝖼𝖾𝗌: 𝗐𝖾 𝗌𝗎𝖼𝖼𝖾𝗌𝗌𝖿𝗎𝗅𝗅𝗒 𝖼𝗅𝗈𝗌𝖾𝖽 𝗈𝗎𝗋 𝗉𝗋𝖾-𝗌𝖾𝖾𝖽 𝖿𝗎𝗇𝖽𝗂𝗇𝗀 𝗋𝗈𝗎𝗇𝖽! 𝖳𝗁𝗂𝗌 𝖿𝗎𝖾𝗅𝗌 𝗈𝗎𝗋 𝗆𝗂𝗌𝗌𝗂𝗈𝗇 𝗍𝗈 𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦 𝐝𝐫𝐮𝐠 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝖻𝗒 𝗁𝖺𝗋𝗇𝖾𝗌𝗌𝗂𝗇𝗀 𝗍𝗁𝖾 𝗉𝗈𝗐𝖾𝗋 𝗈𝖿 𝗌𝗒𝗇𝗍𝗁𝖾𝗍𝗂𝖼 𝖻𝗂𝗈𝗅𝗈𝗀𝗒 (#SynBio), 𝖺𝗋𝗍𝗂𝖿𝗂𝖼𝗂𝖺𝗅 𝗂𝗇𝗍𝖾𝗅𝗅𝗂𝗀𝖾𝗇𝖼𝖾 (#AI), 𝖺𝗇𝖽 𝗁𝗂𝗀𝗁-𝗍𝗁𝗋𝗈𝗎𝗀𝗁𝗉𝗎𝗍 𝗌𝖼𝗋𝖾𝖾𝗇𝗂𝗇𝗀 𝗂𝗇𝗍𝗈 𝐬𝐲𝐧𝐭𝐡𝐞𝐭𝐢𝐜 𝐢𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐜𝐞 𝗍𝗈 𝖾𝗇𝗀𝗂𝗇𝖾𝖾𝗋 𝗇𝖺𝗍𝗎𝗋𝖺𝗅-𝗉𝗋𝗈𝖽𝗎𝖼𝗍-𝗂𝗇𝗌𝗉𝗂𝗋𝖾𝖽 𝖼𝗁𝖾𝗆𝗂𝖼𝖺𝗅 𝖼𝗈𝗆𝗉𝗈𝗎𝗇𝖽𝗌 𝖿𝗈𝗋 𝗁𝗂𝗀𝗁𝗅𝗒 𝖼𝗁𝖺𝗅𝗅𝖾𝗇𝗀𝗂𝗇𝗀 𝖽𝗂𝗌𝖾𝖺𝗌𝖾 𝗍𝖺𝗋𝗀𝖾𝗍𝗌. ✨ 𝖮𝗎𝗋 𝗎𝗇𝗂𝗊𝗎𝖾 𝖺𝗉𝗉𝗋𝗈𝖺𝖼𝗁 𝖺𝗅𝗅𝗈𝗐𝗌 𝗎𝗌 𝗍𝗈: 𝐔𝐧𝐥𝐨𝐜𝐤 𝐧𝐚𝐭𝐮𝐫𝐞'𝐬 𝐩𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥: 𝖶𝖾 𝗅𝖾𝗏𝖾𝗋𝖺𝗀𝖾 AI 𝗍𝗈 𝗎𝗇𝗅𝗈𝖼𝗄 𝗍𝗁𝖾 𝗏𝖺𝗌𝗍 𝗉𝗈𝗍𝖾𝗇𝗍𝗂𝖺𝗅 𝗐𝗂𝗍𝗁𝗂𝗇 𝗇𝖺𝗍𝗎𝗋𝖾'𝗌 𝗆𝗈𝗅𝖾𝖼𝗎𝗅𝖺𝗋 𝗍𝗈𝗈𝗅𝖻𝗈𝗑 𝖺𝗇𝖽 𝖺𝖼𝖼𝖾𝗌𝗌 𝗇𝖾𝗐 𝖼𝗁𝖾𝗆𝗂𝖼𝖺𝗅 𝗌𝗉𝖺𝖼𝖾. 𝐃𝐞𝐬𝐢𝐠𝐧 𝐛𝐞𝐲𝐨𝐧𝐝 𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧: 𝖡𝗒 𝗀𝖾𝗇𝖾𝗍𝗂𝖼𝖺𝗅𝗅𝗒 𝖾𝗇𝗀𝗂𝗇𝖾𝖾𝗋𝗂𝗇𝗀 𝖼𝖾𝗅𝗅𝗌, 𝗐𝖾 𝗉𝗋𝗈𝖽𝗎𝖼𝖾 𝗇𝗈𝗏𝖾𝗅 𝗍𝗁𝖾𝗋𝖺𝗉𝖾𝗎𝗍𝗂𝖼 𝖼𝗈𝗆𝗉𝗈𝗎𝗇𝖽𝗌 𝗍𝗁𝖺𝗍 𝗉𝗎𝗌𝗁 𝖻𝗈𝗎𝗇𝖽𝖺𝗋𝗂𝖾𝗌 𝗈𝖿 𝖽𝗋𝗎𝗀 𝖽𝗂𝗌𝖼𝗈𝗏𝖾𝗋𝗒. 𝐓𝐞𝐬𝐭 𝐦𝐢𝐥𝐥𝐢𝐨𝐧𝐬 𝐨𝐟 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐞𝐬 𝐢𝐧 𝐚 𝐰𝐞𝐞𝐤: 𝖮𝗎𝗋 𝗁𝗂𝗀𝗁-𝗍𝗁𝗋𝗈𝗎𝗀𝗁𝗉𝗎𝗍 𝗌𝖼𝗋𝖾𝖾𝗇𝗂𝗇𝗀 𝖼𝖺𝗉𝖺𝖻𝗂𝗅𝗂𝗍𝗂𝖾𝗌 𝗀𝖾𝗇𝖾𝗋𝖺𝗍𝖾 𝗅𝖺𝗋𝗀𝖾 𝖽𝖺𝗍𝖺𝗌𝖾𝗍𝗌 𝗍𝗈 𝖺𝗂𝖽 𝗆𝗈𝗅𝖾𝖼𝗎𝗅𝖾 𝖽𝖾𝗌𝗂𝗀𝗇 𝖺𝗇𝖽 𝗌𝖾𝗅𝖾𝖼𝗍𝗂𝗈𝗇. 𝖳𝗁𝗂𝗌 𝖿𝗎𝗇𝖽𝗂𝗇𝗀 𝖾𝗆𝗉𝗈𝗐𝖾𝗋𝗌 𝗎𝗌 𝗍𝗈: • 𝖤𝗑𝗉𝖺𝗇𝖽 𝗈𝗎𝗋 𝗐𝗈𝗋𝗅𝖽-𝖼𝗅𝖺𝗌𝗌 𝗌𝖼𝗂𝖾𝗇𝗍𝗂𝖿𝗂𝖼 𝗍𝖾𝖺𝗆 • 𝖪𝗂𝖼𝗄-𝗌𝗍𝖺𝗋𝗍 𝗈𝗎𝗋 𝗂𝗇𝗍𝖾𝗋𝗇𝖺𝗅 𝖽𝗋𝗎𝗀 𝖽𝗂𝗌𝖼𝗈𝗏𝖾𝗋𝗒 𝗉𝗂𝗉𝖾𝗅𝗂𝗇𝖾 • 𝖥𝗈𝗋𝗀𝖾 𝗌𝗍𝗋𝖺𝗍𝖾𝗀𝗂𝖼 𝗉𝖺𝗋𝗍𝗇𝖾𝗋𝗌𝗁𝗂𝗉𝗌 𝗐𝗂𝗍𝗁 𝗅𝖾𝖺𝖽𝗂𝗇𝗀 𝗉𝗁𝖺𝗋𝗆𝖺𝖼𝖾𝗎𝗍𝗂𝖼𝖺𝗅 𝖼𝗈𝗆𝗉𝖺𝗇𝗂𝖾𝗌 𝖬𝗒𝗋𝗂𝖺 𝖡𝗂𝗈𝗌𝖼𝗂𝖾𝗇𝖼𝖾𝗌 𝗂𝗇𝗍𝖾𝗀𝗋𝖺𝗍𝖾𝗌 𝖼𝗎𝗍𝗍𝗂𝗇𝗀-𝖾𝖽𝗀𝖾 𝗌𝖼𝗂𝖾𝗇𝖼𝖾 𝖿𝗋𝗈𝗆 ETH Zürich, ETH-Department of Biosystems Science and Engineering (D-BSSE), the Kenan Bozhüyük lab, and the Helge Bode lab. 𝖶𝖾'𝗋𝖾 𝗀𝗋𝖺𝗍𝖾𝖿𝗎𝗅 𝖿𝗈𝗋 𝗍𝗁𝖾 𝗍𝗋𝗎𝗌𝗍 𝖺𝗇𝖽 𝗌𝗎𝗉𝗉𝗈𝗋𝗍 𝖿𝗋𝗈𝗆 𝗈𝗎𝗋 𝗂𝗇𝗏𝖾𝗌𝗍𝗈𝗋𝗌, 𝗅𝖾𝖽 𝖻𝗒 Creator Fund, and Capital Blue Partners, Manon Cassee, Mosel Ventures, Matthias Frost, Ulrich Meissner, Nikolaus D. Bayer & co. 𝖫𝖾𝗍'𝗌 𝗍𝗋𝖺𝗇𝗌𝖿𝗈𝗋𝗆 𝗁𝗈𝗐 𝗍𝗁𝖾𝗋𝖺𝗉𝖾𝗎𝗍𝗂𝖼𝗌 𝖺𝗋𝖾 𝖾𝗇𝗀𝗂𝗇𝖾𝖾𝗋𝖾𝖽! 🚀 #DrugDiscovery #Biotech #Innovation #Technology #Startups #Entrepreneurship ETH Entrepreneurship #Investment #FutureOfMedicine 𝗁𝗍𝗍𝗉𝗌://𝗐𝗐𝗐.𝗆𝗒𝗋𝗂𝖺.𝖻𝗂𝗈/

    Myria Biosciences — News

    myria.bio

Ähnliche Seiten